Second Time Around: Joint Advisory Committee Will Review Purdue's OxyContin Again
This article was originally published in The Pink Sheet Daily
Purdue's OxyContin will get another advisory committee review Sept. 24, 2009, in light of new data.
You may also be interested in...
Embeda to launch in September backed by 610 sales reps, Chief Commercial Officer Andrzejewski says.
A filing is now expected in mid-2010, although the delay looks to be a bigger hit to Pain Therapeutics than King, S&P analyst says.
Opioid products awaiting FDA approval are not being put on hold for completion of a Risk Evaluation and Mitigation Strategy, said Office of New Drugs Director John Jenkins